tiprankstipranks
Early notable gainers among liquid option names on April 3rd
PremiumThe FlyEarly notable gainers among liquid option names on April 3rd
2M ago
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
PremiumThe Fly
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
2M ago
Viatris announces U.S. commercial launch of Ryzumvi
PremiumThe Fly
Viatris announces U.S. commercial launch of Ryzumvi
2M ago
Viatris sees FY24 adjusted EPS $2.70-$2.85, consensus $2.81
PremiumThe FlyViatris sees FY24 adjusted EPS $2.70-$2.85, consensus $2.81
3M ago
Viatris reports Q4 EPS (64c), consensus 65c
PremiumThe Fly
Viatris reports Q4 EPS (64c), consensus 65c
3M ago
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
PremiumPress Releases
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
3M ago
SPY ETF Update, 2/22/2024
PremiumMarket NewsSPY ETF Update, 2/22/2024
3M ago
SPY ETF Update, 2/20/2024
PremiumMarket News
SPY ETF Update, 2/20/2024
3M ago
SPY ETF Update, 2/16/2024
PremiumMarket News
SPY ETF Update, 2/16/2024
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100